Using GM-CSF to Speed Up Breast Cancer Chemotherapy
Author Information
Author(s): A. Ardizzoni, M. Venturini, M.R. Sertoli, P.G. Giannessi, F. Brema, M. Danova, F. Testore, G.L. Mariani, M.C. Pennucci, P. Queirolol, S. Silvestro, P. Bruzzi, R. Lionetto, F. Latini, R. Rosso
Primary Institution: Istituto Nazionale per la Ricerca sul Cancro, Genoa
Hypothesis
Does the addition of GM-CSF to CEF chemotherapy increase the dose intensity and improve outcomes for patients with advanced breast cancer?
Conclusion
The study found that adding GM-CSF to chemotherapy allowed for a significant increase in dose intensity and improved response rates in patients with advanced breast cancer.
Supporting Evidence
- Patients receiving GM-CSF had a median chemotherapy interval of 16 days compared to 20 days in the control group.
- Response rates improved from 42% in the CEF group to 69% in the CEF + GM-CSF group.
- Non-haematological toxicity was mild, but 50% of patients required dose reduction or suspension of GM-CSF due to side effects.
Takeaway
This study shows that giving a special medicine called GM-CSF with chemotherapy can help patients get their treatment more often and possibly feel better.
Methodology
Patients were randomly assigned to receive either standard CEF chemotherapy or CEF with GM-CSF, and the dose intensity and response rates were compared.
Limitations
The study had a small sample size and was not primarily focused on tumor response.
Participant Demographics
Women aged 18-65 years with advanced breast cancer.
Statistical Information
P-Value
0.02
Confidence Interval
95% CI 49-85%
Statistical Significance
p=0.02
Want to read the original?
Access the complete publication on the publisher's website